Sweden has selected Deep Light Vision AB’s (“DLV”) medical imaging platform as the country’s national use case in the Multilateral Dialogue on Quantum (MDQ), a global collaboration of 13 technologically leading nations. The decision reflects Sweden’s view that DLV’s technology is a strategically important example of how quantum-enabled optics can translate into near-term clinical and commercial value.
DLV’s Ultrasound Optical Tomography (UOT) platform combines clinical ultrasound with laser spectroscopy to generate functional information—such as blood volume and oxygenation (sO₂)—at depths not achievable with conventional optical systems, and without ionizing radiation or contrast agents. The core technology builds on two decades of pioneering quantum-technology research at Lund University under Professor Emeritus Stefan Kröll, now Chief Scientist at DLV.
DLV’s selection for the MDQ highlights growing international interest in technologies that bridge quantum science and real-world healthcare applications. The MDQ brings together Australia, Canada, Denmark, Finland, France, Germany, Japan, Korea, the Netherlands, Sweden, Switzerland, the United Kingdom, and the United States to coordinate policy, talent, and technology development to strengthen the global quantum ecosystem.
“Being chosen as Sweden’s national use case is a strong validation of our technology and its potential impact,” says Stefan Kröll, Chief Scientist. “It gives DLV significant international visibility at a time when clinical adoption and strategic partnerships are accelerating.”
With its novel approach to functional deep-tissue imaging, DLV aims to enable earlier diagnosis, more precise monitoring, and new clinical insights across oncology, critical care, and beyond—opening the door to a new generation of non-invasive medical imaging.